Nivolumab
Bladder Neoplasm
Ikena Oncologymonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Bladder Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ik-175 Ikena Oncology | Phase 1 | CC |
mln8054 Millennium Pharmaceuticals, Inc. | Phase 1 | CC |
Zirconium Zr 89-Dfo-Ys5 Robert Flavell, MD, PhD | Phase 1 | CC |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Armed Forces Hospital, Pakistan | Early Phase 1 | C |
NEPENTHE University of Alberta | N/A | D |
Dilaudid University of Alberta | N/A | D |
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →